Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)

NCT04040322 is registered in ClinicalTrials.gov with Civi Biopharma, Inc. as lead sponsor.

NCT NCT04040322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04040322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Lead sponsor
Civi Biopharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 14, 2019
Completion date
June 9, 2021
Enrollment
198 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

raynaud's phenomenon secondary to systemic sclerosis